| Literature DB >> 35164184 |
Ya-Ming Xu1, E M Kithsiri Wijeratne1, Manping X Liu1, Lijiang Xuan2, Wenqiong Wang2, A A Leslie Gunatilaka1.
Abstract
Withanolides constitute one of the most interesting classes of natural products due to their diversity of structures and biological activities. Our recent studies on withanolides obtained from plants of Solanaceae including Withania somnifera and a number of Physalis species grown under environmentally controlled aeroponic conditions suggested that this technique is a convenient, reproducible, and superior method for their production and structural diversification. Investigation of aeroponically grown Physalis coztomatl afforded 29 withanolides compared to a total of 13 obtained previously from the wild-crafted plant and included 12 new withanolides, physacoztolides I-M (9-13), 15α-acetoxy-28-hydroxyphysachenolide C (14), 28-oxophysachenolide C (15), and 28-hydroxyphysachenolide C (16), 5α-chloro-6β-hydroxy-5,6-dihydrophysachenolide D (17), 15α-acetoxy-5α-chloro-6β-hydroxy-5,6-dihydrophysachenolide D (18), 28-hydroxy-5α-chloro-6β-hydroxy-5,6-dihydrophysachenolide D (19), physachenolide A-5-methyl ether (20), and 17 known withanolides 3-5, 8, and 21-33. The structures of 9-20 were elucidated by the analysis of their spectroscopic data and the known withanolides 3-5, 8, and 21-33 were identified by comparison of their spectroscopic data with those reported. Evaluation against a panel of prostate cancer (LNCaP, VCaP, DU-145, and PC-3) and renal carcinoma (ACHN) cell lines, and normal human foreskin fibroblast (WI-38) cells revealed that 8, 13, 15, and 17-19 had potent and selective activity for prostate cancer cell lines. Facile conversion of the 5,6-chlorohydrin 17 to its 5,6-epoxide 8 in cell culture medium used for the bioassay suggested that the cytotoxic activities observed for 17-19 may be due to in situ formation of their corresponding 5β,6β-epoxides, 8, 27, and 28.Entities:
Keywords: Physalis coztomatl; aeroponic cultivation; anticancer activity; plants of Solanaceae; prostate cancer; withanolides
Mesh:
Substances:
Year: 2022 PMID: 35164184 PMCID: PMC8838488 DOI: 10.3390/molecules27030909
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Major withanolides (1–8) encountered in some aeroponically grown plants of Solanaceae.
Comparison of the number of withanolides and % yields of major withanolides isolated from aeroponically grown and wild-crafted plants of some plants of Solanaceae.
| Plant | Cultivation Method/Source | Number of Withanolides Isolated a | Major Withanolides(% Yield) b | Refs and Notes |
|---|---|---|---|---|
|
| Aeroponics | 14 | Withaferin A ( | [ |
| 2,3-Dihydrowithaferin A-3β-O-sulfate ( | ||||
| Wild-crafted (chemotype I) | 7 | Withaferin A ( | [ | |
|
| Aeroponics | 18 | Physachenolide D ( | [ |
| 15α-Acetoxyphysachenolide D ( | ||||
| Wild-crafted | 5 | Physachenolide D ( | [ | |
| 15α-Acetoxyphysachenolide D ( | ||||
|
| Aeroponics | 25 | Withanolide E ( | [ |
| 4β-Hydroxywithanolide E ( | ||||
| Wild-crafted | 17 | Withanolide E ( | [ | |
| 4β-Hydroxywithanolide E ( | ||||
|
| Aeroponics | 11 | Ixocarpalactone B ( | [ |
| Wild-crafted | 7 | Ixocarpalactone B ( | [ | |
|
| Aeroponics | 29 | Physachenolide C ( | This study |
| Physachenolide D ( | ||||
| Wild-crafted | 8 | Physachenolide C ( | [ | |
| Physachenolide D ( |
a The number of withanolides for wild-crafted/soil-grown plant refers to the referenced study reporting highest yield(s) of the major withanolide(s). b Since 2 is a prodrug of 1 [15], total % yield of withaferin A (1) in aeroponically-grown plant is 0.93. c Yield not reported. d Not encountered in wild-crafted plants [27,28].
Figure 2Structures of withanolides 9–33 encountered in aeroponically grown P. coztomatl (for structures of other withanolides (3–5 and 8) encountered, see Figure 1).
1H and 13C NMR data for 9–12 in CDCl3.
| Position | 9 a | 10 a | 11 | 12 | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 1 | 204.4 | 204.7 | 204.6 | 203.9 | ||||
| 2 | 5.83 (br d, 9.6) | 127.8 | 5.84 (br d, 10.0) | 127.8 | 5.84 (dd, 10.0, 2.0) | 127.7 | 5.85 (dd, 10.0, 2.0) | 127.9 |
| 3 | 6.77 (br d, 9.6) | 145.7 | 6.77 (ddd, 10.0, 4.8, 2.8) | 145.4 | 6.78 (ddd, 10.0, 4.8, 2.4) | 145.9 | 6.76 (ddd, 10.0, 4.8, 2.4) | 145.3 |
| 4 | 3.28 (m) | 33.5 | 3.28 (m) | 33.5 | 3.27 (br d, 21.2) | 33.5 | 3.27 (br d, 21.6) | 33.4 |
| 2.83 (m) | 2.83 (dd, 21.6, 4.8) | 2.83 (dd, 21.2, 2.4) | 2.82 (dd, 21.6, 4.8) | |||||
| 5 | 135.2 | 136.1 | 135.0 | 135.3 | ||||
| 6 | 5.57 (br s) | 124.9 | 5.57 (d, 4.8) | 124.4 | 5.57 (br s) | 124.7 | 5.57 (d, 5.6) | 124.4 |
| 7 | 2.22 (m) | 25.5 | 2.00 (m) | 30.5 | 2.08 (m) | 25.3 | 2.10 (m) | 25.4 |
| 1.82 (m) | 1.62 (m) | 1.81 (m) | 1.81 (m) | |||||
| 8 | 1.85 (m) | 35.1 | 1.69 (m) | 31.9 | 1.82 (m) | 36.2 | 1.80 (m) | 36.4 |
| 9 | 2.37 (m) | 36.0 | 1.76 (m) | 43.4 | 2.07 (m) | 36.1 | 2.15 (m) | 36.1 |
| 10 | 50.8 | 50.6 | 50.6 | 50.8 | ||||
| 11 | 2.31 (m) | 22.0 | 2.34 (m) | 23.3 | 2.15 (m) | 22.3 | 2.21 (m) | 22.0 |
| 1.51 (m) | 1.52 (m) | 1.34 (m) | 1.34 (m) | |||||
| 12 | 2.34 (m) | 24.8 | 2.64 (m) | 25.3 | 2.09 (m) | 27.2 | 1.96 (m) | 27.1 |
| 1.95 (m) | 2.55 (m) | 1.81 (m) | 1.91 (m) | |||||
| 13 | 56.3 | 50.6 | 50.5 | 50.6 | ||||
| 14 | 83.4 | 1.76 (m) | 57.6 | 83.3 | 82.7 | |||
| 15 | 2.43 (m) | 41.2 | 2.09 (m) | 31.9 | 1.59 (dd, 12.2, 9.2) | 32.1 | 1.61 (m) | 32.4 |
| 2.17 (m) | 1.40 (m) | 1.39 (m) | ||||||
| 16 | 5.82 (br s) | 126.7 | 5.74 (br s) | 128.3 | 2.00 (m) | 21.2 | 1.86, (m) | 20.7 |
| 1.88, (m) | ||||||||
| 17 | 151.1 | 153.0 | 2.70 (t, 9.2) | 49.3 | 2.73 (t, 9.7) | 49.9 | ||
| 18 | 4.59 (d, 10.4) | 67.3 | 4.56 (d, 11.2) | 66.6 | 4.40 (d, 11.6) | 62.9 | 4.89, (d, 11.6) | 62.9 |
| 3.99 (d, 10.4) | 4.02 (d, 11.2) | 3.98 (d, 11.6) | 3.70, (d, 11.6) | |||||
| 19 | 1.22 (s) | 18.7 | 1.23 (s) | 18.9 | 1.20 (s) | 18.9 | 1.22 (s) | 18.8 |
| 20 | 74.4 | 74.7 | 76.1 | 76.5 | ||||
| 21 | 1.28 (s) | 24.8 | 1.30 (s) | 26.6 | 1.43 (s) | 23.4 | 1.40 (s) | 20.9 |
| 22 | 4.49 (m) | 80.8 | 4.45 (m) | 81.5 | 4.23 (d, 7.8) | 85.8 | 3.60 (d, 8.4) | 75.9 |
| 23 | 2.50–2.78 (m) | 25.1 | 2.38 (m) | 32.3 | 4.35 (d, 7.8) | 66.9 | 4.06 (dd, 8.4, 8.0) | 81.1 |
| 1.78 (m) | ||||||||
| 24 | 148.2 | 147.6 | 156.7 | 2.32 (m) | 51.0 | |||
| 25 | 123.4 | 123.5 | 124.5 | 2.29 (m) | 37.0 | |||
| 26 | 165.9 | 165.8 | 164.6 | 177.6 | ||||
| 27 | 1.85 (s) | 12.3 | 1.86 (s) | 12.3 | 4.34 (s) | 57.3 | 1.28 (d, 6.8) | 14.1 |
| 28 | 4.46 (m) | 67.7 | 4.45 (m) | 68.0 | 2.06 (s) | 15.4 | 3.83 (dd, 11.2, 2.0) | 63.3 |
| 3.64, (dd, 11.2, 7.6) | ||||||||
| OAc-18 | 2.07 (s) | 21.3 | 2.08 (s) | 21.3 | 2.07 (s) | 21.2 | 2.14 (s) | 21.2 |
| 171.4 | 171.8 | 170.7 | 169.7 | |||||
| Glc-1′ | 4.27 (d, 6.0) | 102.5 | 4.30 (d, 7.2) | 102.5 | ||||
| Glc-2′ | 3.38 (m) | 73.3 | 3.39 (m) | 73.4 | ||||
| Glc-3′ | 3.26 (m) | 75.8 | 3.28 (m) | 75.8 | ||||
| Glc-4′ | 3.55 (m) | 69.4 | 3.60 (m) | 69.8 | ||||
| Glc-5′ | 3.47 (m) | 76.4 | 3.51 (m) | 76.4 | ||||
| Glc-6′ | 3.81 (m) | 61.2 | 3.82 (brs) | 61.5 | ||||
a CDCl3/CD3OD (100:1) was used as the solvent.
1H and 13C NMR data for 13–16.
| Position | 13 a | 14 a | 15 b | 16 c | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 1 | 205.4 | 205.4 | 203.1 | 205.0 | ||||
| 2 | 5.99 (dd, 10.0, 2.8) | 130.0 | 5.98 (dd, 10.0, 2.8) | 129.9 | 5.98 (dd, 10.0, 2.8) | 129.6 | 5.79 (dd, 10.0, 2.0) | 127.7 |
| 3 | 6.97 (ddd, 10.0, 6.0, 2.4) | 147.1 | 6.97 (ddd, 10.0, 6.0, 2.4) | 147.1 | 6.80 (ddd,10.0, 6.4, 2.0) | 144.1 | 6.74 (ddd, 10.0, 4.8, 2.4) | 145.9 |
| 4 | 2.96 (dt, 18.8, 2.4) | 33.8 | 2.96 (dt, 18.8, 2.4) | 33.8 | 2.93 (dt, 18.4, 2.4) | 32.8 | 3.23 (m) | 33.4 |
| 1.94 (m) | 1.94 (m) | 1.85 (m) | 2.79 (dd, 21.6, 4.8) | |||||
| 5 | 63.4 | 63.2 | 62.0 | 134.8 | ||||
| 6 | 3.23 (br s) | 65.0 | 3.20 (d, 2.0) | 65.0 | 3.15 (br s) | 63.9 | 5.57 (d, 5.6) | 125.3 |
| 7 | 1.95 (m) | 27.7 | 2.05 (m) | 27.4 | 1.94 (m) | 26.3 | 2.20 (m) | 25.3 |
| 1.87 (m) | 1.93 (m) | 1.79 (m) | ||||||
| 8 | 1.92 (m) | 35.5 | 2.65 (m) | 35.9 | 1.87 (m) | 34.2 | 1.87 (m) | 34.4 |
| 9 | 1.83 (m) | 38.7 | 1.89 (m) | 38.6 | 1.89 (m) | 36.8 | 2.28 (m) | 35.8 |
| 10 | 49.7 | 49.8 | 48.4 | 50.6 | ||||
| 11 | 2.03 (m) | 24.5 | 2.05 (m) | 24.5 | 2.06 (m) | 22.8 | 2.19 (m) | 22.2 |
| 1.38 (m) | 1.40 (m) | 1.34 (m) | 1.55 (m) | |||||
| 12 | 2.15 (m) | 26.6 | 2.24 (m) | 26.6 | 2.18 (m) | 25.5 | 2.20 (m) | 28.3 |
| 1.89 (m) | 1.85 (m) | 1.68 (m) | 1.47 (m) | |||||
| 13 | 58.6 | 58.6 | 57.5 | 52.2 | ||||
| 14 | 83.0 | 81.3 | 81.5 | 84.5 | ||||
| 15 | 1.62 (m) | 33.8 | 5.06 (dd, 9.2, 8.4) | 77.5 | 1.66 (m) | 32.9 | 2.29 (m) | 39.7 |
| 1.55 (m) | 1.59 (m) | 2.14 (m) | ||||||
| 16 | 2.56 (m) | 37.8 | 2.36 (m) | 43.8 | 2.64 (m) | 37.8 | 5.78 (br s) | 124.5 |
| 1.65 (m) | 2.24 (m) | 1.58 (m) | ||||||
| 17 | 88.9 | 85.8 | 87.9 | 155.9 | ||||
| 18 | 4.36 (d, 11.2) | 65.9 | 4.46 (d, 11.2) | 65.4 | 4.40 (d, 11.6) | 64.7 | 1.11 (s) | 22.3 |
| 4.30 (d, 11.2) | 4.32 (d, 11.2) | 4.28 (d, 11.6) | ||||||
| 19 | 1.19 (s) | 15.3 | 1.20 (s) | 15.4 | 1.20 (s) | 14.8 | 1.18 (s) | 18.6 |
| 20 | 79.8 | 80.0 | 79.2 | 74.6 | ||||
| 21 | 1.39 (s) | 19.0 | 1.35 (s) | 19.1 | 1.43 (s) | 19.0 | 1.26 (s) | 22.4 |
| 22 | 4.86 (dd, 13.6, 3.2) | 83.7 | 4.86 (dd, 13.6, 3.2) | 83.6 | 4.90 (dd, 13.6, 3.2) | 81.3 | 4.37 (t, 8.0) | 81.1 |
| 23 | 3.22 (dd, 18.8, 2.8) | 30.3 | 3.18 (dd, 20.4, 2.0) | 30.3 | 3.14 (m) | 24.5 | 2.63 (m) | 25.0 |
| 2.38 (m) | 2.37 (m) | 2.30, (m) | ||||||
| 24 | 154.9 | 154.9 | 142.3 | 149.0 | ||||
| 25 | 122.4 | 122.4 | 138.1 | 122.8 | ||||
| 26 | 169.1 | 169.0 | 165.6 | 166.2 | ||||
| 27 | 1.88 (s) | 12.1 | 1.87 (s) | 12.1 | 2.35 (br s) | 11.5 | 1.82 (s) | 11.9 |
| 28 | 4.36 (d, 13.6) | 61.9 | 4.37 (d, 14.0) | 61.8 | 10.30 (s) | 190.2 | 4.42 (br s) | 67.7 |
| 4.24 (d, 13.6) | 4.20 (d, 14.0) | |||||||
| OAc-18 | 2.13 (s) | 21.3 | 2.13 (s) | 21.3 | 2.15 (s) | 21.1 | ||
| 173.5 | 173.1 | 170.8 | ||||||
| OAc-15 | 2.06 (s) | 21.4 | ||||||
| 172.6 | ||||||||
| Glc-1′ | 4.23 (d, 8.0) | 102.5 | ||||||
| Glc-2′ | 3.26 (m) | 73.3 | ||||||
| Glc-3′ | 3.23 (m) | 75.9 | ||||||
| Glc-4′ | 3.39 (m) | 69.8 | ||||||
| Glc-5′ | 3.37 (m) | 76.4 | ||||||
| Glc-6′ | 3.79 (dd, 12.0, 2.8) | 61.5 | ||||||
| 3.71 (dd, 12.0, 4.4) | ||||||||
a CD3OD was used as the solvent. b CDCl3 was used as the solvent. c CDCl3/CD3OD (100:1) was used as the solvent.
1H and 13C NMR data for 17–20 in CDCl3.
| Position | 17 | 18 | 19 a | 20 b | 21 b,c | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| 1 | 201.3 | 201.0 | 204.1 | 204.8 | 205.3 | ||||
| 2 | 5.89 (dd, 10.0, 2.4) | 128.6 | 5.89 (dd, 10.0, 2.4) | 128.5 | 5.83 (dd, 10.0, 2.0) | 129.2 | 5.73 (dd, 10.0, 2.8) | 129.0 | 127.8 |
| 3 | 6.62 (br dd, 10.0, 3.6) | 141.2 | 6.63 (ddd, 10.0, 4.8, 2.4) | 141.5 | 6.75 (ddd, 10.0, 4.8, 2.0) | 144.1 | 6.48 (ddd, 10.0, 5.2, 2.0) | 139.6 | 142.2 |
| 4 | 3.49 (br d, 20.0) | 37.2 | 3.53 (dt, 20.4, 2.4) | 37.2 | 3.56 (br d, 20.0) | 38.7 | 2.95 (dt, 18.8, 2.4) | 27.4 | 35.0 |
| 2.49 (m) | 2.47 (dd, 20.4, 8.0) | 2.49 (dd, 20.0, 4.8) | 2.28 (m) | ||||||
| 5 | 79.5 | 79.0 | 82.3 | 81.3 | 77.3 | ||||
| 6 | 4.06 (br s) | 75.0 | 3.97 (br s) | 74.6 | 3.93 (t, 2.9) | 75.6 | 3.86 (brs) | 68.4 | 73.6 |
| 7 | 2.54 (m) | 29.7 | 2.61 (m) | 28.8 | 2.38 (m) | 30.4 | 1.98 (m) | 29.4 | 28.5 |
| 1.52 (m) | 1.54 (m) | 1.54 (m) | 1.37 (m) | ||||||
| 8 | 2.13 (m) | 34.6 | 2.82 (dt, 4.0, 12.0) | 34.8 | 2.26 (m) | 35.9 | 2.02 (m) | 33.9 | 33.4 |
| 9 | 2.76 (m) | 34.9 | 2.37 (dt, 4.0, 12.0) | 34.8 | 2.67 (m) | 36.4 | 2.61 (m) | 33.6 | 33.9 |
| 10 | 53.0 | 52.5 | 54.5 | 52.7 | 51.8 | ||||
| 11 | 2.50 (m) | 22.4 | 2.54 (m) | 22.5 | 2.39 (m) | 24.0 | 2.35 (m) | 22.6 | 22.6 |
| 1.22 (m) | 1.24 (m) | 1.24 (m) | 1.18 (m) | ||||||
| 12 | 2.40 (m) | 26.2 | 2.46 (m) | 26.1 | 2.28 (m) | 27.2 | 2.30 (m) | 26.1 | 26.1 |
| 1.81 (m) | 1.86 (m) | 1.94 (m) | 1.75 (m) | ||||||
| 13 | 57.8 | 58.0 | 58.9 | 57.5 | 57.4 | ||||
| 14 | 81.9 | 80.0 | 83.8 | 82.0 | 82.6 | ||||
| 15 | 1.68 (m) | 32.9 | 5.20 (t, 8.8) | 75.8 | 1.58–1.71 (m) | 33.6 | 1.63 (m) | 32.6 | 32.4 |
| 1.59 (m) | 1.51 (m) | ||||||||
| 16 | 2.71(m) | 37.9 | 2.53 (m) | 42.5 | 2.60 m | 37.8 | 2.61 (m) | 37.4 | 37.0 |
| 1.55 m | 2.26 (m) | 1.68 m | 1.47 (m) | ||||||
| 17 | 88.2 | 84.7 | 89.1 | 87.9 | 87.7 | ||||
| 18 | 4.43 (s) | 65.5 | 4.79 (d, 11.6) | 64.9 | 4.40 (s) | 66.4 | 4.37 (d, 11.2) | 65.5 | 65.3 |
| 4.22 (d, 11.6) | 4.30 (d, 11.2) | ||||||||
| 19 | 1.36 (s) | 16.1 | 1.36 (s) | 16.5 | 1.38 (s) | 17.0 | 1.22 s | 15.4 | 15.5 |
| 20 | 78.9 | 79.4 | 79.9 | 78.2 | 78.1 | ||||
| 21 | 1.41 (s) | 19.3 | 1.38 (s) | 19.2 | 1.40 (s) | 19.2 | 1.31 s | 18.4 | 18.1 |
| 22 | 4.90 (t, 8.4) | 79.7 | 4.91 (br d, 8.0) | 79.7 | 4.90 (m) | 84.0 | 4.84 (dd, 13.6, 3.2) | 80.8 | 81.0 |
| 23 | 2.53 (m) | 33.8 | 2.50 (m) | 33.8 | 2.40 (m) | 30.3 | 2.58 (m) | 33.7 | 33.6 |
| 2.44 (m) | |||||||||
| 24 | 149.7 | 149.9 | 154.9 | 150.6 | 151.0 | ||||
| 25 | 121.8 | 121.8 | 122.5 | 121.4 | 121.2 | ||||
| 26 | 165.7 | 165.7 | 169.2 | 167.2 | 167.5 | ||||
| 27 | 1.88 (s) | 12.4 | 1.88 (s) | 12.4 | 1.89 (s) | 12.1 | 1.82 s | 12.2 | 12.0 |
| 28 | 1.92 (s) | 20.7 | 1.92 (s) | 20.7 | 4.39 (d, 14.0) | 62.0 | 1.88 s | 20.6 | 20.5 |
| 4.23 (d, 14.0) | |||||||||
| OAc-18 | 2.07 (s) | 21.3 | 2.09 (s) | 21.4 | 2.12 (s) | 21.3 | 2.03 s | 21.3 | 21.2 |
| 170.4 | 171.4 | 173.6 | 171.1 | 171.2 | |||||
| OAc-15 | 2.08 (s) | 21.8 | |||||||
| 172.2 | |||||||||
| OMe | 2.93 s | 49.6 | |||||||
a CD3OD was used as the solvent. b CDCl3/CD3OD (100:1) was used as the solvent. c 13C NMR data obtained in CDCl3/CD3OD (100:1) for physachenolide A (21) are included for the purpose of comparison as the reported 13C NMR data for 21 were for CDCl3/DMSO-d6 [38].
Cytotoxicity data of withanolides from Physalis coztomatl against a panel of selected tumor cell lines and normal cells a.
| Compound | Cell Line b | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LNCaP | DU-145 | PC-3 | VCaP | ACHN | WI-38 | ||||||
| Activity | SI c | Activity | SI c | Activity | SI c | Activity | SI c | Activity | SI c | ||
|
| 0.03 ± 0.01 | 15.0 | 0.26 ± 0.01 | 1.7 | 0.06 ± 0.01 | 7.5 | 0.03 ± 0.01 | 15.0 | 1.02 ± 0.20 | 0.4 | 0.45 ± 0.11 |
|
| 2.78 ± 0.66 | >1.8 | >5.0 | 2.90 ± 0.32 | >1.7 | 1.11 ± 0.19 | >4.5 | >5.0 | >5.0 | ||
|
| 1.04 ± 0.18 | 3.6 | 2.67 ± 0.15 | 1.4 | 1.18 ± 0.21 | 3.2 | 0.82 ± 0.11 | 4.6 | 3.98 ± 0.10 | 0.9 | 3.77 ± 0.06 |
|
| 0.03 ± 0.01 | 17.0 | 0.67 ± 0.08 | 0.8 | 0.09 ± 0.01 | 5.7 | 0.08 ± 0.01 | 6.4 | 1.73 ± 0.18 | 0.3 | 0.51 ± 0.03 |
|
| 0.64 ± 0.16 | >7.8 | 4.53 ± 0.55 | >1.1 | 0.86 ± 0.19 | >5.8 | 0.27 ± 0.08 | >18.5 | >5.0 | >5.0 | |
|
| 1.98 ± 0.44 | >2.5 | >5.0 | 2.67 ± 0.21 | >1.9 | 1.26 ± 0.22 | 4.0 | >5.0 | >5.0 | ||
| Doxorubicin | 0.11 ± 0.02 | 0.04 ± 0.01 | 0.34 ± 0.05 | 0.67 ± 0.06 | 0.05 ± 0.01 | 0.80 ± 0.08 | |||||
a Results are expressed as IC50 values in μM. Doxorubicin and DMSO were used as positive and negative controls. b Key: LNCaP = androgen-sensitive human prostate adenocarcinoma; DU-145 = androgen-independent human prostate cancer; PC-3 = androgen-independent human prostate cancer; VCaP = androgen-sensitive human prostate cancer; ACHN = human renal adenocarcinoma; WI-38 = normal human fibroblast cells; c SI = Selectivity Index (against normal cells, WI-38).
Figure 3The HPLC analysis of 5α-chloro-6β-hydroxy-5,6-dihydrophysachenolide D (17) incubated with the cell culture medium (DMEM) showing facile and complete conversion of it to physachenolide C (8).